Clinical Trial Update: Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating GSK239512 for Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• GSK239512 (GSK239512)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED